First line indications for hormonal therapy in prostate cancer;Cancer de la prostate et hormonothérapie : indications thérapeutiques de première ligne

Progres en Urologie

Volumn 20, Issue 2, 2010, Pages 109-115

  Boccon Gibod, L ^a   Richaud, P ^b   Coloby, P ^c   Coulange, C ^d   Culine, S ^e   Davin, J L ^f   Soulie M ^g   Zerbib, M ^h  

^a hôpital Bichat Claude Bernard   (France)

^b INSTITUT BERGONIÉ   (France)

^c CENTRE HOSPITALIER RENÉ DUBOS   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f Service d'urologie   (France)

^g UNIVERSITÉ PAUL SABATIER   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Androgen deprivation; Combined treatment; Intermittent androgen blockade; LHRH agonists; Prostate cancer

Indexed keywords

ANTIANDROGEN; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

BLOOD; CANCER STAGING; DRUG POTENTIATION; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY; SHORT SURVEY; SURVIVAL RATE; TIME;

ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 75149161716     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2009.11.001     Document Type: Short Survey

References (32)

1. Huggins C., and Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
2. Tolis G., et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A 79 5 (1982) 1658-1662
3. Crawford E.D. Hormonal therapy in prostate cancer: historical approaches. Rev Urol 6 Suppl. 7 (2004) S3-S11
4. Peyromaure M., Rebillard A., Ruffion L., Salomon A., Villers M., Soulie, et al. Évolution de la testostéronémie chez les patients traités par hormonothérapie pour un cancer prostatique. Prog Urol 18 1 (2008) 2-8
5. Recommandations 2007 en uro-oncologie AFU, SFRO, GETUG, SFP. Progrès en urologie. 2007, p. 1159-230.
6. Heidenreich A., Aus G., Bolla M., Joniau S., Matveev V.B., Schmid H.P., et al. EAU guidelines on prostate cancer. Eur Urol 53 1 (2008) 68-80
7. HAS. Cancer de la prostate - Guide ALD 30. 2008, www.has-sante.fr.
8. Nair B., Wilt T., MacDonald R., and Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 1 (2002) CD003506
9. Hussain M., Tangen C.M., Higano C., Schelhammer P.F., Faulkner J., Crawford E.D., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24 24 (2006) 3984-3990
10. Choueiri T.K., Xie W., D'Amico A.V., Ross R.W., Hu J.C., Pomerantz M., et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 115 5 (2009) 981-987
11. Messing E.M., Manola J., Yao J., Kiernan M., Crawford D., Wilding G., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 6 (2006) 472-479
12. Wong Y.N., Freedland S., Egleston B., Hudes G., Schwartz J.S., and Armstrong K. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 27 1 (2009) 100-105
13. Siddiqui S.A., Boorjian S.A., Inman B., Bagniewski S., Bergstralh E.J., and Blute M.L. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol 179 5 (2008) 1830-1837 [discussion 1837]
14. Richaud P. Hormonothérapie adjuvante à la radiothérapie. Oncologie 10 (2008) 1-7
15. Pilepich M.V., Winter K., John M.J., Mesic J.B., Sause W., Rubin P., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 5 (2001) 1243-1252
16. Kumar S., Shelley M., Harrison C., Coles B., Wilt T.J., and Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 4 (2006) CD006019
17. Pilepich M.V., Winter K., Lawton C.A., Krisch R.E., Wolkov H.B., Movsas B., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 5 (2005) 1285-1290
18. Hanks G.E., Pajak T.F., Porter A., Grignon D., Brereton H., Venkatesan V., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 21 (2003) 3972-3978
19. Horwitz E.M., Bae K., Hanks G.E., Porter A., Grignon D.J., Brereton H.D., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26 15 (2008) 2497-2504
20. Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 9327 (2002) 103-106
21. Bolla M., de Reijke T.M., Van Tienhoven G., Van den Bergh A.C., Oddens J., Poortmans P.M., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360 24 (2009) 2516-2527
22. Widmark A., Klepp O., Solberg A., Damber J.E., Angelsen A., Fransson P., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373 9660 (2009) 301-308
23. Bolla M., Artignan X., Fourneret P., Brochon D., Ringeisen F., and Descotes J.L. Neoadjuvant hormonal treatment combined with external irradiation in the management of prostate cancer. Bull Cancer 93 11 (2006) 1101-1105
24. Studer U.E., Collette L., Whelan P., Albrecht W., Casselman J., de Reijke T., et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 53 5 (2008) 941-949
25. Lu-Yao G.L., Albertsen P.C., Moore D.F., Shih W., Lin Y., DiPaola R.S., et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300 2 (2008) 173-181
26. Moul J.W., Wu H., Sun L., McLeod D.G., Amling C., Donahue T., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 3 (2004) 1141-1147
27. Ryan C.J., and Small E.J. High risk biochemical relapse and the timing of androgen deprivation therapy. J Urol 176 6 Pt 2 (2006) S61-S65
28. Stewart A.J., Scher H.I., Chen M.H., McLeod D.G., Carroll P.R., Moul J.W., et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23 27 (2005) 6556-6560
29. Eisenberger M.A., Blumenstein B.A., Crawford E.D., Miller G., McLeod D.G., Loehrer P.J., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339 15 (1998) 1036-1042
30. Samson D.J., Seidenfeld J., Schmitt B., Hasselblad V., Albertsen P.C., Bennett C.L., et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95 2 (2002) 361-376
31. Miller K. Randomised prospective study of intermittent versus coutinuous androgen suppresion in advanced prostate cancer. J Clin Oncol 25 No. 18S. (2007) [June 20 supplement]
32. Boccon-Gibod L., Hammerer P., Madersbacher S., Mottet N., Prayer-Galetti T., and Tunn U. The role of intermittent androgen deprivation in prostate cancer. BJU Int 100 4 (2007) 738-743